Businessweek

Pacifichealth Laboratories Inc. announced that it has filed Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock of $0.0025 par value per share under the Securities Exchange Act of 1934, as amended.

Pacifichealth Laboratories Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2012. Revenues were $1,721,119 for the third quarter ended September 30, 2012 compared to $1,971,624 for the same period in 2011. The company said that the biggest impact to revenue in the third quarter was the transitioning from its old formula ACCELERADE and ENDUROX R4 to its new all-natural formulas. Net loss for the third quarter of 2012 was $345,439, or $0.02 per share, compared to a net loss of $116,675, or $0.01 per share for the third quarter of 2011. Loss before other expense and provision for income taxes was $337,880 against $109,420 a year ago. Loss before provision for income taxes was $345,439 against $116,675 a year ago. For the nine months, the company's revenues were $5,701,292 compared to $5,948,461 for the same period in 2011. Net loss for the nine months of 2012 was $454,965, or $0.02 per share, compared to a net income of $2,324, or $0.00 per diluted share, for the nine months ended September 30, 2011. Loss before other expense and provision for income taxes was $439,014 against income of $13,603 a year ago. Loss before provision for income taxes was $454,965 against income of $2,324 a year ago.

Pacifichealth Laboratories Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2012. For the quarter, the company reported net product sales of $2,229,234 against $2,245,226 a year ago. Loss before provision for income taxes was $69,677 against income before provision for income taxes of $91,769 a year ago. Net loss was $69,677 against net income of $91,769 a year ago. For the six months, the company reported net product sales of $3,980,173 against $3,976,837 a year ago. Loss before provision for income taxes was $109,526 against income before provision for income taxes of $118,999 a year ago. Net loss was $109,526 or $0.01 per basic and diluted share against net income of $118,999 or $0.01 per diluted share a year ago.

Pacifichealth Laboratories Inc.’s common stock has been deleted from OTCBB, effective July 23, 2012, due to ineligible for quotation on OTCBB due to quoting inactivity under SEC Rule 15c2-11.

Pacifichealth Laboratories Inc. reported unaudited earnings results for the first quarter ended March 31, 2012. Revenues were $1.751 million compared to $1.732 million a year ago. The company recorded net loss of $0.040 million compared to net income of $0.027 million a year ago. Loss before provision from income taxes was $0.040 million compared to income before provision from income taxes of $0.027 million a year ago. Loss before other (expense) income and provision for income taxes was $0.036 million compared to income before other (expense) income and provision for income taxes of $0.028 million a year ago. The first quarter of 2012 included approximately $0.055 million in expenses as part of the company's investment in internet and social marketing campaigns.